

cated for patients with keratoconus (forme fruste and mild), but surgeons must carefully assess the severity of the disease and the possibility of its progression postoperatively before proceeding with refractive treatment.

“In our experience, PARK treatment on mild and forme fruste keratoconus is safe and effective with careful patient selection.”

Dr. Alpíns has performed PARK on 45 eyes with forme fruste and mild keratoconus. All of the patients had myopic astigmatism and follow-ups ranging from 4 to 10 years. No treated eye has progressed to clinically overt keratoconus. Patients' mean age was 40 years. All signed a consent form that identified the potential risk of developing ectasia after PARK for the treatment of forme fruste and mild keratoconus. Additional inclusion criteria were $\geq 1.50D$ inferior/superior asymmetry, better than 20/40 BCVA, and keratometry readings of $< 50.00D$.

Treating such irregular corneas by refractive parameters alone—manifest or wavefront—does not allow the corneal astigmatism to be minimized adequately. Excessive astigmatic distortion can occur as a result in some patients. I have found it essential to factor the topographic parameters into the treatment plan. In all of my patients, the refractive and corneal astigmatism did not correlate well in magnitude, orientation, or both. One therefore calculates a greater mean ocular residual astigmatism (ie, the vectorial difference between the refractive and corneal astigmatism) than what exists in normal astigmatic eyes.^{16,17} This mean ocular residual astigmatism of 1.07D preoperatively, instead of being neutralized completely on the cornea, was apportioned in part to the refraction and in part to the cornea, effectively targeting less astigmatism remaining on the cornea. Treating by refractive astigmatic values alone leaves an excess amount of corneal astigmatism,¹⁶ which can cause adverse optical effects, particularly on a keratoconic cornea.

Using vector planning, corneal parameters can be incorporated into the refractive treatment strategy. In this way, the amount of corneal astigmatism remaining is reduced without compromising the refractive astigmatic outcome. At 12 months postoperatively, all eyes had 20/30 vision or better uncorrected at distance, and there was no loss of BCVA. Leaving less corneal astigmatism postoperatively has the potential to reduce higher-order aberrations and improve patients' BCVA.

CONCLUSION

In our experience, PARK treatment on mild and forme fruste keratoconus is safe and effective with careful patient selection. The key parameters indicating the risk of ectasia associated with PARK treatments will become more apparent with further advances in technology and more data. Until then, using topographic as well as refractive data that have been constant over at least 2 years, together with the likely nonprogression of the keratoconus, provide guidance for extremely satisfying outcomes for patients and their surgeons. ■

Noel Alpíns, FRANZCO, FRACS, FRCOphth, FACS, is Medical Director at NewVision Clinics in Melbourne, Australia. He has a financial interest in the Assort computer program for planning and outcomes analysis used for the calculation of treatment parameters for PARK. Dr. Alpíns may be reached at +61 3 95846122; nalpins@unimelb.edu.au.



George Stamatelatos, BSc Optom, is Senior Clinical Optometrist at NewVision Clinics in Melbourne, Australia. He acknowledged no financial interest in any company or product mentioned herein. Dr. Stamatelatos may be reached at stama@newvisionclinics.com

- Rabinowitz YS, Rasheed K. KISA% index: a quantitative videokeratography algorithm embodying minimal topographic criteria for diagnosing keratoconus. *J Cataract Refract Surg.* 1999;25:1327-1335.
- Alio JL, Shabayek MH, Artola A, et al. Fourier analysis for normal, keratoconus and keratoconus suspect eyes. Paper presented at the Annual AAO Meeting; October 16, 2005; Chicago, IL.
- Colin J, Velou S. Current surgical options for keratoconus. *J Cataract Refract Surg.* 2003;29:379-386.
- Reeves SW, Stinnett S, Adelman RA, Afshari NA. Risk factors for progression to penetrating keratoplasty in patients with keratoconus. *Am J Ophthalmol.* 2005;140:607-611.
- Maleceze F, Couillet J, Calvas P, et al. Corneal ectasia after photorefractive keratectomy for low myopia. *Ophthalmology.* 2006;113:742-746.
- Lafond G, Bazin R, Lajoie C. Bilateral severe keratoconus after laser in situ keratomileusis in a patient with forme fruste keratoconus. *J Cataract Refract Surg.* 2001;27:1115-1118.
- Binder PS. Ectasia after laser in situ keratomileusis. *J Cataract Refract Surg.* 2003;29:2419-2429.
- Durand L, Monnot JP, Burillon C, Asi A. Complications of radial keratotomy eyes with keratoconus and late wound dehiscence. *J Refract Corneal Surg.* 1992;8:311-314.
- Ellis W. Radial keratotomy in a patient with keratoconus. *J Refract Corneal Surg.* 1992;18:406-409.
- Mortensen J, Ohrstrom A. Excimer laser photorefractive keratectomy for treatment of keratoconus. *J Refract Corneal Surg.* 1994;10:368-372.
- Bilgihan K, Ozdek SC, Konuk O, et al. Results of photorefractive keratectomy in keratoconus suspects at 4 years. *J Refract Surg.* 2000;16:438-443.
- Kremer I, Shochot Y, Kaplan A, Blumenthal M. Three year results of photoastigmatic keratectomy for mild and atypical keratoconus. *J Cataract Refract Surg.* 1998;24:1581-1588.
- Sun R, Gimbel HV, Kaye GB. Photorefractive keratectomy in keratoconus suspects. *J Cataract Refract Surg.* 1999;25:1461-1466.
- Binder PS, Lindstrom RL, Stulting RD, et al. Keratoconus and corneal ectasia after LASIK. *J Cataract Refract Surg.* 2005;31:2035-2038.
- Rabinowitz YS, Maumenee IH, Lundergan MK, et al. Molecular genetic analysis in autosomal dominant keratoconus. *Cornea.* 1992;11:302-308.
- Alpíns N. Astigmatism analysis by the Alpíns method. *J Cataract Refract Surg.* 2001;27:31-49.
- Alpíns N. New method of targeting vectors to treat astigmatism. *J Cataract Refract Surg.* 1997;23:65-75.